Examining factors that affect mast cell growth in mastocytosis
Official title: Regulation of the Proliferation and Survival of Normal and Neoplastic Human Mast Cells
Run by National Institutes of Health Clinical Center (CC) · NCT00044122 · Data updated 2026-11-12
This study is trying to understand what causes mast cells to grow too much in people with mastocytosis, so we can find better treatments for them.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 1 Day to 80 Years |
| Sex | All |
| Enrollment | 700 (estimated) |
| Sponsor | National Institutes of Health Clinical Center (CC) NIH |
| Locations | 1 site (Bethesda, Maryland) |
| Status | Recruiting |
| Started | September 18, 2002 |
| Registry record updated | November 10, 2026 |
| Trial ID | NCT00044122 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals aged 0 to 80 with a confirmed diagnosis of mastocytosis.
✕Probably not a fit
Patients with severe anemia or other conditions that contraindicate participation may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study investigates the growth factors that influence mast cell proliferation in patients with mastocytosis, a condition characterized by an excess of mast cells. Participants, aged 0 to 80, will undergo a comprehensive evaluation at the NIH Clinical Center, including medical history, physical exams, blood tests, and bone marrow biopsies. The goal is to understand the molecular mechanisms behind mastocytosis to improve future therapies. The study will also collect clinical data and biological specimens for further research.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and treatment options for patients with mastocytosis.
How similar studies have gone: While this study focuses on specific growth factors in mastocytosis, similar studies have shown promise in understanding mast cell biology and related conditions.
Who can join: the full rules
Show full inclusion / exclusion criteria
* PATIENT PARTICIPANT INCLUSION CRITERIA: Participants with mastocytosis zero to 80 years of age may participate in telehealth visits, and two to 80 years of age may participate on-site at NIH Clinical Center Histologic evidence of increased mast cell number by bone marrow and/or skin biopsy or documentation of mastocytosis in the skin supported with a photograph of diagnostic skin lesions Must be under the care of a primary care physician to be enrolled. Ability to provide informed consent. PATIENT PARTICIPANT EXCLUSION CRITERIA: Anemia with hemoglobin \< 8 g/dL, hematocrit \< 24. Any condition that in the opinion of the investigator contraindicates participation in this study. RELATIVE INCLUSION CRITERIA: Two to 80 years of age. A biological relative without the diagnosis of mastocytosis by skin examination or histologic evidence in a skin or bone marrow biopsy Participant has a primary medical care provider outside the NIH Ability to provide informed consent. RELATIVE EXCLUSION CRITERIA: Any condition that in the opinion of the investigator contraindicates participation in this study.
Where it's running
-
National Institutes of Health Clinical Center
Bethesda, Maryland, United States Recruiting
Study contacts
- Principal investigator: Hirsh D Komarow, M.D. — National Institute of Allergy and Infectious Diseases (NIAID)
- Study coordinator: Hye Jeong C Bolan, R.N.
- Email: bolanhy@mail.nih.gov
- Phone: (301) 594-1233
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Different forms of IgE in health and disease.
We will test whether different forms of IgE in the blood differ between healthy adults and people with allergies, chronic spontaneous urticaria, recent anaphylaxis, mastocytosis, hereditary alpha tryptasemia, X‑linked agammaglobulinemia, or those undergoing venom/medication desensitization.
-
Budoprutug for adults with immune thrombocytopenia (ITP)
This trial will test whether two IV doses of budoprutug are safe and can help raise platelet counts in adults with ITP who still have platelets under 30,000/µL after prior treatment.
-
Finding causes of allergic reactions during and after surgery
This project tests whether measuring tryptase levels and doing skin tests can find the cause of suspected allergic reactions during or after surgery for patients aged 2 and older.
-
Registry for Rare Diseases
This study is creating a detailed registry to collect information on rare diseases like amyloidosis and sarcoidosis to help improve how they are diagnosed and treated.
-
Registry for patients with mastocytosis and hypertryptasemia
This study is collecting information and samples from patients with mastocytosis and high tryptase levels at the University Hospital of Zurich to better understand their conditions and improve treatment.
-
Exploring the role of sclerostin in bone disease related to mastocytosis
This study is trying to see how levels of a protein called sclerostin affect bone health in adults with mastocytosis compared to healthy volunteers.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.